Illumina's cancer diagnostics spinoff, which has raised more than $1.9bn in funding, has filed to float on the Nasdaq Global Select Market.
Grail, a US-based medical diagnostics technology developer that has raised more than $1.9bn in funding from investors including a range of corporates, filed for a $100m initial public offering yesterday.
Morgan Stanley, Goldman Sachs and BofA Securities are lead bookrunners for the IPO while Cowen and Evercore ISI are also bookrunners. The $100m represents a placeholder figure and the offering is set to take place on the Nasdaq Global Select Market.
Founded in 2015 by genomics technology producer Illumina,…
